Double-Hit Lymphoma (DHL) is an aggressive form of lymphoma, so doctors typically recommend intensive treatment. Here's what treatment generally looks like:
Common chemotherapy regimens include
- DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin + rituximab)
- R-Hyper-CVAD (rituximab + Show Full Answer
Double-Hit Lymphoma (DHL) is an aggressive form of lymphoma, so doctors typically recommend intensive treatment. Here's what treatment generally looks like:
Common chemotherapy regimens include:
- DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin + rituximab)
- R-Hyper-CVAD (rituximab + cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine)
- R-CODOX-M/R-IVAC (alternating drug combinations including rituximab)
These are more intensive than the older R-CHOP regimen, which wasn't as effective for DHL. Other treatment options may include:
- Bone marrow transplant — recommended for those who respond well to chemotherapy, allowing higher chemo doses by replacing damaged bone marrow cells with healthy ones
- CNS prophylaxis — since DHL has a higher risk of spreading to the brain and spinal cord, chemotherapy (often methotrexate) may be delivered directly to the central nervous system
- CAR T-cell therapy — a newer immunotherapy showing promising results, especially for relapsed or treatment-resistant cases Regarding survival rates, DHL is often diagnosed at an advanced stage, and it can sometimes be resistant to treatment or relapse after an initial response. One study found that around 50% of people with DHL were alive after two years, with 40% of those showing no signs of disease progression.
The good news is that new treatments and clinical trials are actively improving outcomes. It's really worth asking your oncologist about clinical trials that might give access to newer therapies.
Every person's situation is different, so a conversation with your care team will give you the clearest picture of what to expect based on your specific case.
August 20
Join
Your Privacy Choices
